Historical and current end-of-day data provided by FACTSET. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype. 52 week low is the lowest price of a stock in the past 52 weeks, or one year. Argen X SE – ADR 52 week low is $267.35 as of April 29, 2023. 52 week high is the highest price of a stock in the past 52 weeks, or one year.
Argenx does not have a long track record of dividend growth. There may be delays, omissions, or inaccuracies in the Information. The industry with the best average Zacks Rank would be considered the top industry , which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank would place in the bottom 1%.
SVB Securities Reaffirms Their Buy Rating on Argenx Se (ARGX)
The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. We’d like to share more about how we work and what drives our day-to-day business. CompareARGX’s historical performanceagainst its industry peers and the overall market.
- 18 Wall Street equities research analysts have issued «buy,» «hold,» and «sell» ratings for argenx in the last year.
- According to analysts’ consensus price target of $452.94, argenx has a forecasted upside of 16.8% from its current price of $387.88.
- If you want to revitalize your portfolio with some exciting opportunities, these biotech stocks to buy might fit the bill.
- A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.
- Stocks with similar financial metrics, market capitalization, and price volatility to ARGENX SE are TGTX, GLYC, GERN, RETA, and LXRX.
This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.27% per year. These returns cover a period from January 1, 1988 through April 3, 2023.
Price Target and Rating
High institutional ownership can be a signal of strong market trust in this company. In the past three months, argenx insiders have not sold or bought any company stock. MarketBeat has tracked 9 news articles for argenx this week, compared to 3 articles on an average week. Argenx has a short interest ratio («days to cover») of 4.2. 1.70% of the outstanding shares of argenx have been sold short. With a price/sales ratio of 2,014.54, ARGENX SE has a higher such ratio than 99.71% of stocks in our set.
Short interest in argenx has recently increased by 1.65%, indicating that investor sentiment is decreasing.
A Bearish Sign Appears On argenx’s Chart
An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s. Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data. Take your analysis to the next level with our full suite of features, known and used by millions throughout the trading world. Argenex SE might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 . © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.
A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the presentation. Zacks Earnings ESP looks to find companies that have recently seen positive earnings estimate revision activity. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. The scores are based on the trading styles of Value, Growth, and Momentum. There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score.
According to 13 analysts, the average rating for ARGX stock is «Strong Buy.» The 12-month stock price forecast is $452.85, which is an increase of 16.75% from the latest price. According to analysts’ consensus price target of $452.94, argenx has a forecasted upside of 16.8% from its current price of $387.88. Argenx has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.
Provide specific https://1investing.in/ and services to you, such as portfolio management or data aggregation. A stock’s beta measures how closely tied its price movements have been to the performance of the overall market. Argenx is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
Fundamentally, the driving catalyst for biotech stocks to buy centers on the possibility of supporting paradigm-shifting medical breakthroughs. For example, a report published by the JAMA Network indi… Raised $65 million in an IPO on Thursday, May 18th 2017. The company issued 3,600,000 shares at a price of $18.18 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. Sign-up to receive the latest news and ratings for argenx and its competitors with MarketBeat’s FREE daily newsletter.
How has ARGX performed historically compared to the market?
Argenx developed and is commercializing the neonatal Fc receptor blocker in the U.S., Japan, and the EU. Its product pipeline includes product candidates such as ARGX-117, ARGX-118, ARGX-115, ARGX-116, and others. 18 Wall Street equities research analysts have issued «buy,» «hold,» and «sell» ratings for argenx in the last year. There are currently 1 hold rating and 17 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should «buy» ARGX shares. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors.
These are established germany narrowly avoids recession despite commerce that reliably pay dividends. The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding.
Argenx SE operates as a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. It operates from the Netherlands, Belgium, the United States of America, Japan, Switzerland, Germany and France. It evaluates efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. De Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Breda, the Netherlands. It is engaged in the business of developing a pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. The group has partnered with academic researchers through its Immunology Innovation Program and aims to translate immunology breakthroughs into a portfolio of novel antibody-based medicines.
Stocks with similar financial metrics, market capitalization, and price volatility to ARGENX SE are TGTX, GLYC, GERN, RETA, and LXRX. The technique has proven to be very useful for finding positive surprises. Let us take a look at some biotech stocks, ARGX, BMRN, LLY and GMAB, which are poised to beat on third-quarter earnings. Real-time analyst ratings, insider transactions, earnings data, and more. The P/E ratio of argenx is -29.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. If you want to revitalize your portfolio with some exciting opportunities, these biotech stocks to buy might fit the bill.
We have 9 different ratings for every stock to help you appreciate its future potential. Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies. High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks.
- Maintaining independence and editorial freedom is essential to our mission of empowering investor success.
- High institutional ownership can be a signal of strong market trust in this company.
- As for revenue growth, note that ARGX’s revenue has grown -75.11% over the past 12 months; that beats the revenue growth of only 2.32% of US companies in our set.
- The consensus among Wall Street equities research analysts is that investors should «buy» ARGX shares.
- We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view.
Below are the latest news stories about ARGENX SE that investors may wish to consider to help them evaluate ARGX as an investment opportunity. As for revenue growth, note that ARGX’s revenue has grown -75.11% over the past 12 months; that beats the revenue growth of only 2.32% of US companies in our set. ARGX scores best on the Sentiment dimension, with a Sentiment rank ahead of 96.96% of US stocks.
Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations.